High Q Technologies and Creative Biostructure Announce Strategic Partnership Expanding Global Access to Quantum-Enabled EPR Spectroscopy
2.6.2026 15:00:00 CEST | Business Wire | Press Release
High Q Technologies, a developer of quantum-enabled electron paramagnetic resonance (EPR) spectroscopy systems, and Creative Biostructure, a structural biology Contract Research Organization, today announced a strategic partnership to support broader adoption of EPR spectroscopy for studying protein dynamics in pharmaceutical and biotechnology research.
EPR spectroscopy is increasingly relevant as drug discovery turns toward disordered, flexible, and disease‑relevant protein systems that cannot be fully understood through static structural methods alone. However, broad adoption of EPR has historically been limited by instrument and workflow complexity, and the need for dedicated technical expertise in experimental design and data interpretation. Leveraging quantum sensor technology, FATHOM® EPR has overcome these challenges.
By providing unique measurements of long‑range distances, FATHOM® EPR enables researchers to probe conformational ensembles and molecular motion implicated in today’s most challenging health conditions where intrinsic disorder, aggregation, and dynamic intermediates drive pathology. Through the collaboration, Creative Biostructure will provide scientific consultation, experimental design support, and workflow guidance for organizations implementing High Q Technologies’ FATHOM® EPR spectroscopy platform.
“Drug discovery is increasingly focused on understanding how proteins behave in motion,” said Don Carkner, Managing Director at High Q Technologies. “With FATHOM®, quantum-enabled EPR spectroscopy provides a way to study these dynamic systems, and through this partnership with Creative Biostructure, we are making these capabilities more accessible within structural biology and drug discovery workflows.”
Tony Zhang, Principal Scientist at Creative Biostructure, said, “Modern structural biology is moving towards integrating synergistic techniques to understand complex biomolecular systems. EPR spectroscopy adds an important layer of dynamic information that complements methods such as cryo-EM, NMR spectroscopy, and computational modeling.”
Organizations interested in Creative Biostructure’s EPR spectroscopy services or additional information can visit https://www.creative-biostructure.com/quantum-epr-spectroscopy-platform.htm.
About High Q Technologies
High Q Technologies is an innovative company that develops EPR spectrometers for protein dynamics, powered by quantum sensor technology. High Q is on a mission to redefine protein structure determination, the future of drug discovery, and the development of novel therapeutics.
Learn more about High Q Technologies and FATHOM® at http://www.highqtechnologies.com
About Creative Biostructure
Creative Biostructure provides structural biology services including cryo-EM, NMR spectroscopy, X-ray crystallography, membrane protein characterization, and structure-based drug discovery support. The company supports global research organizations in protein structure determination and molecular characterization across a range of therapeutic areas.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260602896746/en/
Contacts
Media
High Q Technologies
Glen Gregory
Director of Sales and Marketing
glen.gregory@highqtechnologies.com
Creative Biostructure
Tony Zhang
Principal Scientist
xinyan.zhang@creative-biostructure.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™17.8.2026 21:44:00 CEST | Press Release
Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee and represents a major milestone in the company’s clinical and regulatory development strategy. The trial will be conducted at The Panama Clinic in Panamá City under the leadership of Drs. Juan Osorio and Emilio Tufiño, experienced sports medicine surgeons, with Dr. Osorio serving as Principal Investigator for the study. Dr. Osorio stated, “I am pleased to be the Principal Investigator for this important study, and we look forward to contributing the data that will support a larger clinical study and subsequent market entry.” Nanochon selected Panamá for its growing reputa
TOURISE and Oxford Economics Release New Global Report on Tourism Resilience in an Era of Permanent Disruption17.8.2026 16:33:00 CEST | Press Release
TOURISE, in collaboration with Oxford Economics, today released a new report, “Resilience in a World that Doesn’t Reset: Redesigning Tourism for an Era of Permanent Disruption.” The analysis of 85 major crises over two decades shows a clear pattern: in a world defined by continuous shocks, destinations that act before disruption hits recover up to 1.5 times faster than those that wait. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260817880835/en/ “In a world that does not reset between crises, disruption is a constant feature of the global tourism landscape,” said His Excellency Ahmed Al-Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE. “The real test for destinations measures how they prepare for volatility, protect traveler confidence, and maintain continuity ahead of such events.” Using the current Middle East crisis as a lens, where Gulf hubs carry roughly 14 percent of global transit traffic, the r
The Expensify Visa® Commercial Card Brings New Proactive Spend Controls to 14 Countries17.8.2026 15:00:00 CEST | Press Release
Expensify, Inc. (Nasdaq: EXFY), the easiest way to manage expenses, travel, and corporate cards, today expanded the reach of Expensify Card spend rules, the market-leading way for businesses to control corporate card spend before it happens. Available to businesses in 14 countries, spend rules let admins decide exactly how, where, and when each Expensify Card can be used, so only compliant transactions go through. Unlike traditional corporate cards that rely on after-the-fact expense review, the Expensify Card enforces policy at the point of purchase. Admins set the rules once, and the card handles the rest. With Expensify Card spend rules, admins can: Lock a card to a subscription. Give each recurring SaaS tool its own virtual card, so a vendor can only ever charge what it should. If the card owner changes teams or leaves, the subscription keeps running, with no swapping cards and no missed payments. Cover a one-time purchase. Issue a virtual card for a single transaction like event r
Riskified Analysis Finds Travel Fraudsters Are Adapting Faster Than Traditional Signals Can Keep Up, With May Flight Risk Up 32%17.8.2026 14:30:00 CEST | Press Release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released new findings from its Travel Industry Insights report, revealing how sophisticated fraud rings and AI-enabled fraudsters are evolving their tactics across airlines, hotels, and online travel platforms. Riskified’s analysis shows that fraudsters are increasingly adapting their behavior to resemble legitimate travelers, making traditional fraud indicators less reliable and creating new challenges for travel merchants. Riskified’s analysis of hundreds of millions of travel transactions across flights, hotels, and land transportation found that flight fraud risk increased through the first five months of 2026, with May 2026 marking the sharpest year-over-year increase at 32% compared to May 2025. The findings show that sophisticated fraud activity is not limited to predictable travel peaks, with organized fraud rings continuously adjusting their methods throughout the year. Riskified's travel n
PIF Delivers Strong Revenue and Profit Growth in 202517.8.2026 13:54:00 CEST | Press Release
PIF today published its 2025 Annual Report demonstrating strong financial performance and continued progress against its long-term objectives. As a long-term investor with a unique mandate to drive the economic transformation of Saudi Arabia and deliver sustainable financial returns, PIF maintained a diversified portfolio in 2025, balancing returns with national impact and long-term resilience. Maintaining Financial Discipline In 2025, revenue rose 9% year on year to $120 billion, while net profit more than doubled to $17 billion, supported by stronger contributions from maturing portfolio companies. PIF retained over $900 billion in assets under management and achieved an annualized total shareholder return of 5.8% since 2017. Total shareholder return in 2025 was positively driven by increased dividends from portfolio companies and returns from financial investments. It was also impacted by downward movements in the valuations of some assets, as a result of wider market conditions, an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom